Terumo and NAMSA Form Strategic Outsourcing Partnership

October 15, 2024—Terumo and NAMSA announced a strategic outsourcing partnership. The companies stated that NAMSA’s clinical research, testing, and consulting services will help accelerate the regulatory approval and commercialization of Terumo’s product portfolio globally.

NAMSA is a medical device–focused contract research organization headquartered in Toledo, Ohio.

Terumo, based in Tokyo, Japan, and operates globally, provides medical solutions in more than 160 countries and regions. Its business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments.

“We strongly believe that the establishment of a global strategic partnership with NAMSA will enable us to realize a seamless, end-to-end development program that covers from feasibility studies to product launches on a global scale,” commented Toshihiko Osada, Group Senior Managing Executive Officer, Terumo Corporation, in the company’s press release. “This partnership is a pivotal step toward bringing cutting-edge technology and innovation to physicians and patients worldwide and we are excited about the journey ahead.”

John Amat, NAMSA Chief Commercial Officer, added, “We are thrilled to facilitate Terumo’s growth through this strategic outsourcing partnership. As part of this partnership, we have granted Terumo immediate access to clinical experts for study starts and capacity in addition to our skilled and talented teams of clinical and regulatory medical device experts. Together, we’ll accelerate the introduction of life-enhancing devices.”

The companies’ press release noted that the global MedTech industry is experiencing changing regulatory requirements and increasing clinical evidence demands. More stringent requirements can extend development timelines, increase costs, and slow speed-to-market.

NAMSA’s strategic outsourcing solution and full suite of in-house services (clinical, preclinical, testing, regulatory) aim to allow MedTech innovators to proactively mitigate risk, preserve capital, and create more stakeholder value. The results include accelerated commercialization and products that are more readily available to patients who need them most, stated the companies.